Immunization Schedule For Children And Adolescents Aged 18 Years Or Younger (Page 7 of 8) in pdf

For further guidance on the use of the vaccines mentioned below, see:

• For other catch-up guidance, see Figure 2.

Catch-up vaccination

vaccination of persons with high-risk conditions and

Influenza vaccines. (Minimum age: 6 months for inacti-

• Ensure that all persons aged 7 through 18 years without

other persons at increased risk” and “Meningococcal B

vated influenza vaccine [IIV], 18 years for recombinant

evidence of immunity (see MMWR 2007;56[No. RR-4],

vaccination of persons with high-risk conditions and other

influenza vaccine [RIV])

available at

persons at increased risk of disease” below.

Routine vaccination:

) have 2 doses of

Catch-up vaccination:

• Administer influenza vaccine annually to all children

varicella vaccine. For children aged 7 through 12 years,

• Administer Menactra or Menveo vaccine at age 13 through

beginning at age 6 months. For the 2016–17 season,

the recommended minimum interval between doses is

18 years if not previously vaccinated.

use of live attenuated influenza vaccine (LAIV) is not

3 months (if the second dose was administered at least 4

• If the first dose is administered at age 13 through 15 years,

recommended.

weeks after the first dose, it can be accepted as valid); for

a booster dose should be administered at age 16 through

For children aged 6 months through 8 years

persons aged 13 years and older, the minimum interval

18 years, with a minimum interval of at least 8 weeks

• For the 2016–17 season, administer 2 doses (separated by

between doses is 4 weeks.

between doses.

at least 4 weeks) to children who are receiving influenza

10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)

• If the first dose is administered at age 16 years or older, a

vaccine for the first time or who have not previously

Routine vaccination

booster dose is not needed.

received ≥2 doses of trivalent or quadrivalent influenza

• Initiate the 2-dose HepA vaccine series at ages 12 through

• For other catch-up guidance, see Figure 2.

vaccine before July 1, 2016. For additional guidance,

23 months; separate the 2 doses by 6 to 18 months.

Clinical discretion:

follow dosing guidelines in the 2016–17 ACIP influenza

• Children who have received 1 dose of HepA vaccine

• Young adults aged 16 through 23 years (preferred age

vaccine recommendations (see MMWR August 26,

before age 24 months should receive a second dose 6 to

range is 16 through 18 years) who are not at increased

2016;65(5):1-54, available at

18 months after the first dose.

risk for meningococcal disease may be vaccinated with a

• For any person aged 2 years and older who has not

2-dose series of either Bexsero (0, ≥1 month) or Trumenba

• For the 2017–18 season, follow dosing guidelines in the

already received the HepA vaccine series, 2 doses of

(0, 6 months) vaccine to provide short-term protection

2017–18 ACIP influenza vaccine recommendations.

HepA vaccine separated by 6 to 18 months may be

against most strains of serogroup B meningococcal

For persons aged 9 years and older:

administered if immunity against hepatitis A virus

disease. The two MenB vaccines are not interchangeable;

• Administer 1 dose.

infection is desired.

the same vaccine product must be used for all doses.

Measles, mumps, and rubella (MMR) vaccine. (Minimum

Catch-up vaccination

• If the second dose of Trumenba is given at an interval of

age: 12 months for routine vaccination)

• The minimum interval between the 2 doses is 6 months.

<6 months, a third dose should be given at least 6 months

Routine vaccination

Special populations

after the first dose; the minimum interval between the

• Administer a 2-dose series of MMR vaccine at ages 12

• Administer 2 doses of HepA vaccine at least 6 months apart

second and third doses is 4 weeks.

through 15 months and 4 through 6 years. The second

to previously unvaccinated persons who live in areas where

Meningococcal conjugate ACWY vaccination of persons

with high-risk conditions and other persons at increased

dose may be administered before age 4 years, provided at

vaccination programs target older children, or who are at

least 4 weeks have elapsed since the first dose.

increased risk for infection. This includes persons traveling

risk:

• Administer 1 dose of MMR vaccine to infants aged 6

to or working in countries that have high or intermediate

Children with anatomic or functional asplenia (including

through 11 months before departure from the United

endemicity of infection; men having sex with men; users

sickle cell disease), children with HIV infection, or children

States for international travel. These children should be

of injection and non-injection illicit drugs; persons who

with persistent complement component deficiency

revaccinated with 2 doses of MMR vaccine, the first at age

work with HAV-infected primates or with HAV in a research

(includes persons with inherited or chronic deficiencies

12 through 15 months (12 months if the child remains in

laboratory; persons with clotting-factor disorders; persons

in C3, C5-9, properdin, factor D, factor H, or taking

an area where disease risk is high), and the second dose at

with chronic liver disease; and persons who anticipate

eculizumab [Soliris]):

least 4 weeks later.

close, personal contact (e.g., household or regular

▪ Menveo

• Administer 2 doses of MMR vaccine to children aged

babysitting) with an international adoptee during the first

ɱ Children who initiate vaccination at 8 weeks. Administer

12 months and older before departure from the United

60 days after arrival in the United States from a country

doses at ages 2, 4, 6, and 12 months.

States for international travel. The first dose should be

with high or intermediate endemicity. The first dose should

ɱ Unvaccinated children who initiate vaccination at 7

administered on or after age 12 months and the second

be administered as soon as the adoption is planned, ideally,

through 23 months. Administer 2 primary doses, with

dose at least 4 weeks later.

2 or more weeks before the arrival of the adoptee.

the second dose at least 12 weeks after the first dose

Catch-up vaccination

11. Meningococcal vaccines. (Minimum age: 6 weeks for

AND after the first birthday.

• Ensure that all school-aged children and adolescents

Hib-MenCY [MenHibrix], 2 months for MenACWY-CRM

ɱ Children 24 months and older who have not received a

have had 2 doses of MMR vaccine; the minimum interval

[Menveo], 9 months for MenACWY-D [Menactra], 10 years

complete series. Administer 2 primary doses at least 8

between the 2 doses is 4 weeks.

for serogroup B meningococcal [MenB] vaccines: MenB-

weeks apart.

Varicella (VAR) vaccine. (Minimum age: 12 months)

4C [Bexsero] and MenB-FHbp [Trumenba])

▪ MenHibrix

Routine vaccination

Routine vaccination:

ɱ Children who initiate vaccination at 6 weeks. Administer

• Administer a 2-dose series of VAR vaccine at ages 12

• Administer a single dose of Menactra or Menveo vaccine

doses at ages 2, 4, 6, and 12 through 15 months.

through 15 months and 4 through 6 years. The second

at age 11 through 12 years, with a booster dose at age 16

ɱ If the first dose of MenHibrix is given at or after age 12

dose may be administered before age 4 years, provided

years.

months, a total of 2 doses should be given at least 8

at least 3 months have elapsed since the first dose. If the

• For children aged 2 months through 18 years with high-

weeks apart to ensure protection against serogroups

second dose was administered at least 4 weeks after the

risk conditions, see “Meningococcal conjugate ACWY

C and Y meningococcal disease.

first dose, it can be accepted as valid.

Immunization Schedule For Children And Adolescents Aged 18 Years Or Younger Page 7

Related Articles

Related forms

Related Categories